> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Emigality Misses Superiority in Clinical Trial
- URL: https://www.fdaweb.com/emigality-misses-superiority-in-clinical-trial/
- Published: 2023-06-16T12:00:00.000Z
- Updated: 2026-09-14T18:39:34.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154711

Eli Lilly says a head-to-head clinical trial comparing its migraine drug Emgality (galcanezumab-gnlm) to Pfizer’s Nurtec ODT (Rimegepant) did not meet the primary endpoint — Emgality’s statistical superiority to Nurtec. Lilly says the drugs’ response rates were similar, but Emgality “performed numerically better on key secondary endpoints” in the three-month trial. The primary endpoint in the 580-patient trial was defined as “statistical superiority to Nurtec ODT on the percentage of participants achieving a 50% or greater reduction in monthly migraine headache days.” Lilly says it will disclose the full results of the CHALLENGE-MIG trial later this year.

Monoclonal antibody Emgality was approved 9/2018 for preventing migraines in adults. In 6/2019, it was approved for treating episodic cluster headaches in adults.